'Sandoz will be the Leading Biosimilar Drug Company in 2012, With Revenue Of $308 Million' Predicts New Visiongain Report

'Sandoz will be the Leading Biosimilar Drug Company in 2012, With Revenue Of $308 Million' Predicts New Visiongain Report PR Newswire LONDON, October 4, 2012 LONDON, October 4, 2012 /PRNewswire/ -- A new report by Visiongain predicts that Sandoz will retain its position as the global leader in the biosimilar drugs market in 2012. In that year, its three follow-on biologics will achieve $308m in revenue. Combined revenue for the top three companies in that market will grow with a CAGR of close to 25% between 2011 and 2016. Those findings, and others, appear in Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2012-2022, published in October 2012. Visiongain's analysis indicates that, in 2011, the top ten biosimilar drug manufacturers accounted for 54.8% of that market. Global generics manufacturers occupied three of the top four places in the ranking. Leading manufacturers based in India, China and South Korea were also among the top ten biosimilar manufacturers. All companies among the top 25 will experience revenue growth in the coming 10 years, although most will have market share fall. Richard Lang, a pharmaceutical industry analyst for visiongain, said: "Many of the top 25 biosimilar manufacturers have an established base in the market, having marketed products for the past five to ten years. However, many will see their position challenged in the coming decade.